<DOC>
	<DOCNO>NCT00264160</DOCNO>
	<brief_summary>This open-label , multicenter trial evaluate efficacy safety treatment AMN107 chronic myelogenous leukemia ( CML ) patient resistant and/or intolerant imatinib mesylate therapy .</brief_summary>
	<brief_title>Efficacy Safety Oral AMN107 Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant Imatinib Mesylate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Imatinib resistant intolerant Philadelphia chromosomepositive CML blast crisis , accelerate chronic phase Males females â‰¥ 18 year age Impaired cardiac function Acute chronic liver renal disease Use therapeutic coumadin Central nervous system ( CNS ) infiltration Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AMN107</keyword>
	<keyword>CML</keyword>
	<keyword>Bcr Abl</keyword>
	<keyword>cytogenetic response</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>imatinib mesylate</keyword>
</DOC>